Introduction
Hepatitis C is a serious threat to a significant percentage (1-2%) of the global population. This review summarizes the course of the disease and existing treatments, describes products under investigation and explains their mode of action on direct and indirect antiviral targets. Direct viral targets are those that are encoded by the viral genome. Indirect viral targets are those encoded by the host cell genome and are functions that are either usurped by the virus to allow its propagation or play important roles in the immune response and immunomodulation. We discuss here some exciting approaches to discovering and exploiting novel, cellular or indirect antiviral targets as potential therapies. These targets might be exploited to serve as a basis for the generation of new and powerful medications against hepatitis C.
HCV: the disease and its consequences
Chronic viral hepatitis is a common disease. More than 500 million people suffer from chronic viral hepatitis worldwide, due to chronic infection with hepatitis B virus, hepatitis D virus or hepatitis C virus (HCV) . Chronic viral hepatitis is the main cause of cirrhosis and hepatocellular carcinoma (HCC), which are responsible for major morbidity and mortality worldwide. There are 350 million cases of chronic hepatitis B infection and 170 million cases of chronic hepatitis C infection (Marcellin & Boyer, 2003) . With no prophylactic or therapeutic vaccines available to date, this will create a major health crisis during the next decade. HCV escapes the immune system and establishes a persistent infection in approximately 75% of cases. These chronic carriers are at risk of developing life-threatening liver disease, such as cirrhosis and HCC. Five million The development of novel antiviral drugs against hepatitis C is a challenging and competitive area of research. Progress of this research has been hampered due to the quasispecies nature of the hepatitis C virus, the absence of cellular infection models and the lack of easily accessible and highly representative animal models. The current combination therapy consisting of interferon-α and ribavirin mainly acts by supporting host cell defence. These therapeutics are the prototypic representatives of indirect antiviral agents as they act on cellular targets. However, the therapy is not a cure, when considered from the long-term perspective, for almost half of the chronically infected patients. This draws attention to the urgent need for more efficient treatments. Novel anti-hepatitis C treatments under study are directed against a number of so-called direct antiviral targets such as polymerases and proteases, which are encoded by the virus. Although such direct antiviral approaches have proven to be successful in several viral indications, there is a risk of resistant viruses developing. In order to avoid resistance, the development of indirect antiviral compounds has to be intensified. These act on host cell targets either by boosting the immune response or by blocking the virus host cell interaction. A particularly interesting approach is the development of inhibitors that interfere with signal transduction, such as protein kinase inhibitors. The purpose of this review is to stress the importance of developing indirect antiviral agents that act on host cell targets. In doing so, a large source of potential targets and mechanisms can be exploited, thus increasing the likelihood of success. Ultimately, combination therapies consisting of drugs against direct and indirect viral targets will most probably provide the solution to fighting and eradicating hepatitis C virus in patients.
Keywords: HCV, interferon, ribavirin, indirect (cellular) and direct (viral) antiviral targets, (in)direct antiviral agent/compound, protein kinase, signal transduction, glutathione peroxidase people in Europe and 4 million people in the USA are chronically infected, with an estimated 20-50% of these patients likely to develop cirrhosis within the next 20-30 years (Vogel, 2003) . The entire spectrum of outcome ranges from a very slow progression over 50 years to an accelerated progression to cirrhosis within 5 years . In retrospective studies of post-transfusion hepatitis C, some 20-50% developed cirrhosis and 5-25% developed HCC after 10-30 years (Durantel et al., 2003) (Figure 1 ). Cases of decompensated liver cirrhosis ultimately undergo liver transplantation. Even after liver transplantation, the rate of relapses is high, which is most probably due to extrahepatic infection, subsequently resulting in reinfection of the transplanted liver. Several reports indicate that HCV can also infect organs and cell types other than the liver, particularly lymphoid cells (Dammacco et al., 2000) . Furthermore, HCV RNA can persist at very low levels in the serum and peripheral lymphoid cells and can persist in peripheral blood monocytes for many years after spontaneous or antiviral therapy-induced resolution of chronic hepatitis C (Pham et al., 2004) . Negative-strand HCV RNA has been reported in the brain, providing evidence that the central nervous system is an additional site of HCV replication (Forton et al., 2004) . This may explain the cerebral dysfunction found in chronically HCV-infected patients. These extrahepatic infections might contribute to the immune-mediated pathogenesis of chronic liver disease and/or the development of autoimmune diseases, including mixed cryoglobulinaemia. The presence of abnormal serum levels of cryoglobulins can damage the kidneys and cause glomerulonephritis, a kidney disease affecting the capillaries of the glomeruli (the compact cluster of capillaries in the kidney that filter blood). The protein is characterized by oedema, raised blood pressure and excess protein in the urine.
A prognosis for chronically infected HCV patients can be made, relying on biochemical and histological parameters (Marcellin & Boyer, 2003) . Important parameters for the long-term prognosis of chronically infected patients are the initial level of viral load in the serum and the early virological response towards interferon (IFN) treatment (Durantel et al., 2003) . In general,~25% of patients have normal serum alanine aminotransferase (ALT) levels despite detectable HCV RNA in serum; liver histological lesions are generally mild, cirrhosis is rare and their prognosis is good. The majority,~50%, of chronically infected patients progress very slowly and the long-term risk of developing cirrhosis is low. Approximately 25% of the chronically infected patients have moderate to severe chronic hepatitis. Liver biopsies are used to diagnose 
Incidences and transmission
De novo infections are still considered to occur at the rate of 20-25 cases per 100000 persons per year (Vogel, 2003) . HCV is mainly transmitted through contact with blood and blood products, with blood transfusions and sharing of non-sterilized needles and syringes being the main routes (Poynard et al., 2003) . With the advent of routine blood screening for HCV antibodies in 1991, transfusion-related hepatitis C has almost disappeared and the incidence has been in decline (Marcellin & Boyer, 2003) .
Treatments and perspectives
Because of the small number of symptomatic patients, randomized trials to identify new regimens in acute hepatitis C have been rare. So far, the standard treatment for chronic HCV infection, IFN-α, has been found to be effective for acute hepatitis C (Poynard et al., 2003) . The aim of the antiviral therapy is to cure viral infection and thereby prevent the progression of liver disease towards cirrhosis and HCC. Ten years ago, IFN-α monotherapy was approved by the Food and Drug Administration (FDA) as the basis of therapies for chronic viral hepatitis . Subsequently, a combination treatment (Davis et al., 1998; McHutchinson et al., 1998) , consisting of IFN-α and ribavirin (Sidwell et al., 1972) was introduced 6 years ago. The IFN-α/ribavirin combination has been considerably improved by the introduction of pegylated interferons (PEG-IFNs) (Vogel, 2003) . Using either PEG-IFN-α2b (PEG-Intron®; Schering-Plough, Kenilworth, NJ, USA) or PEG-IFN-α2a (Pegasys®; Hoffmann-LaRoche, Basel, Switzerland) in combination with ribavirin (Rebetol®; Schering-Plough or Copesus®; Hoffmann-LaRoche), sustained viral responses (SVRs) as high as 46-65% have been achieved for chronically infected patients ( Figure 1 ). These clinically manifested results have turned the combination treatment into the most efficacious therapy for HCV currently available (Vogel, 2003) .
Only a minor fraction of chronically infected patients receive medication, indeed, less than 1%. The costs of complications, including decompensated cirrhosis and liver transplantation, may far exceed the medication costs for PEG-IFN-α/ribavirin treatment. In the absence of a more affordable combination treatment, we expect a pharmacoeconomic health crisis for the industrialized world, let alone in the major areas of virus dissemination in Asia, with a total of 9 million people infected with HCV in the USA and Europe (Vogel, 2003) . Since 35-54% of patients are still non-responders to the currently existing and expensive therapies, it has become obvious that there is a huge need for novel treatment alternatives and medications. Without effective treatment strategies, HCV-related morbidity and mortality are expected to increase nearly threefold by the year 2015. The age-adjusted death rate in 1999 was 1.8 per 100 000 persons in the USA (Kim, 2002) . The development of small molecule drugs will become particularly important as they are typically associated with lower production and development costs. Novel treatment options should not only address the patient population of IFN non-responders, but also try to shorten the overall treatment period, which currently takes up to 24 months. Equally important, although difficult to achieve due to the quasispecies nature of HCV (a quasispecies is a family of closely related, but slightly different, viral genomes; viral genetic variants, derived from the original infecting virus, which are present during an infection) and the large number of HCV genotypes, is the development of preventive and therapeutic vaccines, which are currently being tested in Phase II clinical trials (Pawlotsky & McHutchison, 2004) .
HCV biology
HCV has been classified as the sole member of a distinct genus, Hepacivirus, in the family Flaviviridae, which also includes flaviviruses and pestiviruses. Originally cloned in 1989 (Choo et al., 1989) , the viral genome is now well characterized. HCV is an enveloped particle harbouring a plus-strand RNA molecule that is ~9600 nucleotides in length (Bartenschlager & Lohmann, 2000; Bartenschlager, 2002) . The initiation of translation is mediated by the interplay of host and viral factors. An internal ribosome entry side (IRES), a complex RNA structure located at the 5′ non-coding region, serves to bind directly to ribosomes to initiate protein synthesis (Durantel et al., 2003; Bartenschlager, 2002) . The open reading frame (ORF) encodes a polyprotein of ~3000 amino acids in length, which is processed by both cellular and viral proteases into at least 10 discrete polypeptides (Figure 2A ). The structural proteins (core or capsid, gpE1 and gpE2) are used for the assembly of new-progeny virus particles, whereas most of the non-structural (NS) proteins (p7, NS2, NS3, NS4A, NS4B, NS5A and NS5B) participate in the replication of the viral genome. During viral replication, the viral genome acts as a template for the synthesis of negative-strand RNA, which, in turn, is a template for the production of excess amounts of positive-strand RNA progeny. Details concerning the initiation of the synthesis of the positivestrand RNA are not clearly known and only sparse information is available in terms of initial and late phases, for example, entry and morphogenesis of viral particles, since the field lacks a reproducible and efficient cell culture system for viral replication (Bartenschlager & Lohmann, 2000; Bartenschlager, 2002; Dymock et al., 2000) .
HCV consists of six different genotypes (genotypes 1-6). Knowledge of the genotype or serotype is helpful for prediction of SVR and the choice of treatment duration. Genotypes do not change during the course of an infection. Response rates to treatment with the combination of PEG-IFN and ribavirin are 88% for genotypes 2 and 3, and 48% for genotypes 1, 4, 5 and 6 (Poynard et al., 2003) . Unfortunately, genotype 1 is the most frequent genotype in Europe and the USA and is present in 60-80% of cases (Marcellin & Boyer, 2003) . These insufficient response rates underscore the need for the development of novel and efficient genotype- Signal peptidase
The major structural proteins include the core (C) and the envelope proteins (E1 and E2). The non-structural proteins p7, NS2, NS3, NS4A/NS4B and NS5A/NS5B are indicated. At the 5′ non-translated region (NTR) resides the internal ribosomal entry site (IRES), which is highly conserved and represents a site for development of translation inhibitors such as antisense oligonucleotides, ribozymes and small intefering RNAs (siRNAs). NS3 encodes a protein with a specific protease and helicase activity. The NS5A region encodes for a phosphoprotein and the NS5B for an RNA-dependent RNA polymerase enzyme, both important for viral replication. They also represent sites for the development of specific viral enzyme inhibitors. Other potential enzyme targets include the HCV-specific proteases (NS2/3 and NS3). These enzymes are involved in processing the viral polyprotein at specific sites as indicated. (B) The subgenomic replicon has been generated by replacing the region that encodes the core protein up to the NS2-encoding region by the neomycin phosphotransferase gene (neo) and the IRES of the encephalomyocarditis virus (EMCV). This IRES drives the translation of the HCV polypeptide from NS3 to NS5B, whereas the selectable marker neo is expressed under the control of the original HCV IRES of the 5′ non-translated region.
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Tissue culture model: the replicon system
Many aspects of HCV disease can only be addressed in vivo, for example, the influence of the immune system. For many investigatiors, however, it is sufficient and desirable to work with a less complex, well-controlled system in vitro. The recently generated HCV-replicon system, in which expression of the HCV non-structural proteins drives the replication of a subgenomic HCV RNA, fulfills these criteria (for reviews, see Bartenschlager & Lohmann, 2001; Bartenschlager, 2002) .
The human hepatoma cell line (Huh-7) was transfected with subgenomic HCV RNAs called replicons (Lohmann et al., 1999) . These were derived from a cloned full-length HCV genome of genotype 1b (Figure 2A ) by replacing the reading frame for the N-terminal proteins (including p7 or NS2) with the neomycin phosphotransferase gene (neo) downstream of the HCV IRES. Translation of the HCV NS2-5B or NS3-5B region was directed by the IRES of the encephalomyocarditis virus (EMCV) inserted downstream of the neo gene ( Figure  2B ). Upon transfection of Huh-7 cells, only those in which HCV RNA replication occurs develop continuous resistance against the drug geniticin due to neo expression. Cell lines obtained from such resistant colonies contain high levels of replicon RNAs and viral proteins (Lohmann et al., 1999; Pietschmann et al., 2001) . This allows the study of HCV RNA replication as well as of translation and processing of those HCV proteins present in the system (Figure 2 ).
The development of subgenomic replicons containing HCV non-structural proteins that replicate in human hepatoma cells, now provides a system to test or screen candidate drugs that target the non-structural gene products. Thus, the antiviral efficacy of BILN 2061, a NS3 protease inhibitor, the development of which was put on hold after entering Phase II clinical trials (see Table 1 ), was determined in the HCV replicon cell culture system. BILN 2061 has an IC 50 of 4 nM (genotype 1a) and 3 nM (genotype 1b), while cytotoxicity analysis in parental Huh-7 cells produced a cytotoxic concentration (CC 50 ) of 16-35 µM (Pause et al., 2003; Lamarre et al., 2003) . As these subgenomic replicons do not produce infectious virions, the option of studying encapsidation or cell-to-cell viral transmission is not provided. Furthermore, the replicon cell lines are of clonal origin and have, apart from adaptive mutations, identical HCV sequences (Krieger et al., 2001) . However, the genetic heterogeneity of HCV suggests that future drugs should display activity against a broad range of HCV genotypes, subtypes and quasispecies.
In summary, the HCV-replicon RNA replicates to fairly high levels in Huh-7 cells and provides, for the first time, a genetic system to study HCV RNA replication and a cellbased assay screen for HCV inhibitors. Such a repliconbased screen for anti-HCV substances has been described in a recent study on the nucleoside antimetabolite-mediated reduction of HCV RNA (Stuyver et al., 2003) . In this study, a specific anti-HCV replicon effect was defined as minimal interference with the exponential cell growth, minimal reduction in cellular host RNA levels and reduction of the HCV RNA copy number per cell compared with that of the untreated control (Stuyver et al., 2003) .
Animal models
Developing robust animal model systems for HCV is highly desirable and some progress has recently been achieved (reviewed by Pietschmann & Bartenschlager, 2003) . Besides the fact that ethical considerations do not permit experiments with humans, an animal system may allow for monitoring of the entire cycle of viral replication, from infection of naive tissues to full-blown viraemia. Since acute HCV infection often happens without any obvious symptoms, these patients do not consult a physician. Thus, valuable information about early events of HCV infection and remission is lacking. A model system will allow the study of each phase of the disease under controlled conditions. Establishing a model system is hampered by the fact that HCV infects only humans and chimpanzees, primarily targeting hepatocytes. The determinants of the restricted host and tissue specificity are not understood. Despite the extremely robust replication rate of HCV in humans, efforts to propagate this virus in cell culture have been frustratingly unsuccessful. Therefore, the use of surrogate virus models closely related to HCV, such as the bovine viral diarrhoea virus (BVDV) and the tamarin GB virus-B (GBV-B), both which belong to Flaviviridae, provides alternative approaches. GBV-B is most closely related to HCV and is, therefore, a good surrogate model. For instance, one potential mechanism of action of the pleiotropic antiviral agent, ribavirin, was verified using the GBV-B model. The antiviral effect of ribavirin does not seem to be solely based on the inhibition of inosine 5′-monophosphate dehydrogenase (IMPDH) and reduction of intracellular pools of GTP and dGTP, but also by the incorporation of ribavirin triphosphate into viral RNA and induction of error-prone replication . However, the biological activity of a tested compound in these systems does not necessarily translate into efficacy for human HCV infection.
Transplant mouse models
Mice are the preferred models for scientific studies for a number of reasons (for example, short breeding cycles, 
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r Phase II trials have been halted and further development of this drug is reportedly suspended owing to cardiac toxicity in non-human primates at a supra-efficacious dose. £ Rigel have just announced insignificant clinical effects for R803 in a Phase I/II HCV trial due to poor bioavailability (http://www.rigel.com/rigel/corporate). Underlined text represents indirect antiviral targets or host cell targets, which are modulated through the treatment. Italic text represents direct antiviral targets. There are two exceptions: viramidine since it is a modified version of ribavirin. Ribavirin is a pleiotropic agent, exerting direct and indirect antiviral effects. The same is true for amantadine, since amantadine does not only target the virally encoded M2 proton channel (Lear, 2003) . Amantadine is an antagonist of the N-methyl D-aspartate receptor as well (Magnet et al., 2004) . simple handling and genetic characterization). Mice cannot be infected directly with HCV due to the restricted host range of the virus. Therefore, transgenic mice expressing one or several viral proteins were created to analyse their effects on liver pathology, but their meaningfulness for drug development remains somewhat unclear.
Significantly more progress has been reported on the generation of transplant mouse models. These transplant mouse models might lead to the development of more suitable small animal models in the future. Propagation of HCV in these chimeric mouse models has recently been achieved (Mercer et al., 2001; Ilan et al., 2002) .
The principle of the first model is that immunocompromised mice, unable to develop murine hepatocytes due to a transgene, were engrafted with human hepatocytes isolated from fresh livers and shown to be susceptible to HCV infection and replication. To achieve this system, Mercer and colleagues transplanted human hepatocytes into immunodeficient transgenic mice (SCID, homozygous for the SCID trait) carrying the urokinase-type plasminogen-activator gene controlled by the albumin promoter (Alb-uPA mice). The Alb-uPA transgenic mouse, developed in 1990 to study neonatal bleeding disorders, carries a tandem array of four murine urokinase genes controlled by an albumin promoter. This transgene targets urokinase over-production to the liver resulting in a profoundly hypofibrinogaenemic state and accelerated hepatocyte death. Normal human hepatocytes were transplanted into these SCID mice carrying the plasminogen activator transgene Alb-uPA, thus generating mice with chimeric human livers. After inoculation with infected human serum, viral infection persisted beyond 4-5 weeks only in homozygous Alb-uPA mice. The shorter persistence of infection in Alb-uPA heterozygous mice is attributed to a much lower survival of transplanted human hepatocytes in these mice relative to homozygous mice. Approximately 75% of homozygous Alb-uPA mice inoculated with serum from hepatitis C patients developed HCV titres. The viral titres reached 3×10 4 -3×10 6 copies/ml in the blood of infected mice and were equal to or higher than those present in patients with chronic hepatitis C. This novel mouse model supports prolonged HCV infection for 15-17 weeks, and even for 35 weeks in one mouse. Infection could be serially passaged through three generations of mice, confirming both synthesis and release of infectious viral particles. Thus, this is the first murine model that may be suitable for studying human HCV in vivo (Mercer et al., 2001) . However, this system is laborious and requires special expertise to isolate and transplant human hepatocytes and to maintain a colony of fragile immunodeficient mice with an approximately 35% mortality in newborns due to a defect in blood coagulation. This may be the reason why, 3 years after its introduction into the scientific community, this system has not reached a broad application. There is also a scientific obstacle: in humans with chronic hepatitis C, the injury of hepatocytes is not directly caused by HCV infection but rather is a consequence of the destruction of infected hepatocytes by cytotoxic lymphocytes. A crucial question is whether these mice will develop liver disease confined to the transplanted human hepatocytes or whether the immunosuppressed mice will be infected but free of disease.
In another approach, immunodeficient BNX mice were irradiated with a lethal dose, rescued by transplantation of bone marrow cells originating from severe combined immunodeficient SCID mice and finally, had liver fragments from ex vivo HCV-infected humans transplanted under the kidney capsule (Galun et al., 1995) . The resulting system, made up from three genetically disparate sources of tissue, was termed 'Trimera'. Viraemia (positive-strand HCV-RNA levels) in HCV-Trimera mice peaked at approximately day 18 after liver transplantation, and viral replication in liver grafts was evidenced by the presence of specific negative-strand HCV RNA. Recently, it was claimed that up to 85% of the transplanted animals of this Trimera-mouse system were HCV-infected and that an antibody was effective in reducing the viraemia in this model (Ilan et al., 2002) . This anti-HCV monoclonal antibody (MAb) HCV AB XTL 68 was developed from the peripheral blood lymphocytes of an HCV-positive patient. It was characterized as a fully human high-affinity IgG1 subtype MAb against the HCV E2 envelope protein. The antibody was further developed and is currently being studied in clinical trials for chronic HCV patients (HepeX™-C in Table 1 ). So far, the antibodies have been shown to be safe, tolerable and could significantly reduce viral load (Ilan et al., 2002; Dagan & Eren, 2003) .
Another antiviral drug, I70, inhibiting HCV RNA translation, was also effective in reducing the viraemia in this model. The I70 molecule was selected via highthroughput screening in a cell-based IRES assay designed for screening of HCV IRES inhibitors (Ilan et al., 2002) .
In conclusion, both systems should help to expedite anti-HCV drug evaluation if available to the pharmaceutical industry without extreme costs and legal complications, but they also have their limitations, especially in light of the role of host cell targets, which play an important role in the immune response and the HCV replication process.
Chimpanzee model
Until recently the only well-established animal model supporting HCV replication was the chimpanzee model. The successful infection of this animal was invaluable for the initial characterization of HCV, which finally led to the identification of infectious cDNA clones of the virus (Choo et al., 1989) . The clinical course of virus infection observed in chimpanzee and humans shows some similarities. Apart from humans, chimpanzees are the only other natural hosts known to become infected with HCV. On the other hand, HCV pathogenesis in humans and chimpanzees has its distinctions, particularly in terms of developing a chronic infection (Bigger et al., 2001) . Initial viraemia is accompanied by elevated aminotransferase levels, which is a surrogate marker indicating the beginning of liver damage (Shimizu et al., 1990) . The cellular innate immune response is crucial for the clearance of HCV in both chimpanzees and humans (Rehermann et al., 2000) , but unlike humans, chimpanzees do not seem to develop fibrosis and cirrhosis. Nevertheless, since there is close correlation between many clinical parameters detected in chimpanzee and man, experiments with this animal will continue to deliver valuable data critical for drug development in the future (Farci et al., 1992; Kolykhalov et al., 1997) . A disadvantage is that work with this endangered species, like the exotic murine models, is expensive and restricted to only a few centres.
There is obviously a need for better cellular and animal models. Nevertheless, a few development candidates have been evaluated and shown to be active in the existing models, such as VX-950 in the murine models (Alb-uPA transgenic mouse) and NM283 in the chimpanzee model (VX-950 is a small molecule protease inhibitor from a new class of antiviral drugs that inhibit hepatitis C NS3-4A protease and NM283 is an inhibitor of the RNA-polymerase NS5B). Both enzymes are considered to be essential for HCV viral replication. These two agents are now in clinical development (see Table 1 ). These proof-of-concept experiments prove the animal models valid to a certain extent. Given the differences regarding virus propagation and replication in the surrogate HCV animal models, the question arises about the overall value of such highly sophisticated models for decision-making in the drug development process with respect to the classic question of which animal is the ideal surrogate model for humans.
Our opinion on animal models for drug testing in HCV is as follows. Firstly, we suggest using at least one of these currently available mouse models in hepatitis C drug discovery programmes for direct antiviral agents before promoting those compounds into further preclinical and clinical development. This is relevant when the compound(s) of interest are readily bioavailable in mice or can be made bioavailable without major optimization efforts. It should be kept in mind that the pharmacokinetic and pharmacodynamic properties of a candidate compound might differ significantly when compared in animals and humans, and tedious chemical optimization processes for the adaptation of potential drugs to proof-of-concept studies in mice should be avoided. In the particular case that significant adaptation of compounds for their use in mice would be necessary, we suggest moving them forward as directly as possible into pre-clinical development instead. Secondly, the situation is different and more complicated for indirect antiviral agents. Target selection typically relies on peculiarities of the host-virus relationship in humans. Therefore, candidate drugs should be tested for activity in the replicon system only if the underlying target identification and validation processes were based on the use of the replicon system as a cellular model as well. The projection of such results into rather artificial animal models might be very risky. Therefore, lead compounds resulting from an indirect antiviral strategy with activity in the replicon system should be subsequently optimized in terms of bioavailability and pharmacology. Such optimized lead compounds might then be moved directly forward to testing in humans, without performing a proof-of-concept study in animals.
Current treatments and HCV development pipeline
Interferons IFNs are human cytokines discovered in the late 1950s. They were appropriately named 'interferons' because of their ability to interfere with viral replication and production (Isaacs & Lindenmann, 1957) . In addition, IFNs are potent regulators of cell growth and have immunomodulatory activity. IFNs are classified as type I or 'viral' IFNs (IFN-α and IFN-β), which induce signalling via the type I IFN-receptor, and type II IFN or IFN-γ, which binds to the type II interferon receptor . On a molecular level, the IFNs bind to their receptors, which in turn leads to activation of the Janus kinase ( Jak)/signal transducer and activators of the transcription (STAT) signalling pathway (Darnell et al., 1994; Heim, 2000) . Activation of the Jaks induces phosphorylation of the STATs. Phosphorylated STATs dimerize and translocate to the nucleus in order to induce gene activation through binding to the IFN-α-stimulated response elements (ISREs) or to the IFN-γ-activated site (GAS) in the cases of IFN-α/β and IFN-γ, respectively (Darnell et al., 1994) .
Soon after the initial molecular identification and characterization of HCV as the causative agent of the parenterally transmitted form of the virally induced non-A, non-B hepatitis in 1989 (Choo et al., 1989) , standard IFN-α ( Figure 3) regimen monotherapy was approved for HCV in 1990 (Poynard et al., 2003) . There are more than 15 different genes encoding at least 25 different IFN-α homologues in man (Doly et al., 1998; Katze et al., 2002) . Three members of this family (IFN-α2a, IFN-α2b and IFN-α-n1) have been approved for the treatment of hepatitis C. The addition of recombinant IFN in cases of viral infections such as HCV, boosts the innate immune response and typically shifts the Th1/Th2 balance towards a Th1 response, supporting endogenous IFN and other cytokines in order to fight the viruses . As such, IFN treatment represents a prototypical host cell approach for treating viral infections. Initially, IFN-α2a and IFN-α2b have been chosen as treatments for HCV (see Table 2 ). Standard IFN-α monotherapy has a limited efficacy, leading to an SVR of 16-30% after 48 weeks of therapy (Table 2) . Efficacy has been improved to an SVR of 41-45% by introducing the combination treatment of standard IFN-α and the synthetic guanosine analogue, ribavirin (Poynard et al., 1998; McHutchinson et al., 1998) . The latest achievement was the introduction of the longlasting PEG-IFNs (Figure 3 ) in combination with ribavirin (Manns et al., 2001; Fried et al., 2002) (Table 2) . Despite these successes in constantly improving the existing IFN-α therapies, there is still a large patient population that does not respond to PEG-IFN/ribavirin therapy. Depending on the genotype of the underlying viral infection, between ~50%-90% of patients actively respond to the combination treatment in terms of sustained viral response (Poynard et al., 2003) . However, the largest HCV patient population in the Western world is patients with genotype 1, who are particularly resistant to therapy.
An interesting treatment alternative is represented through other type I IFN such as IFN-β and also consensus IFN (CIFN). CIFN is already on the market and might have advantages (Table 2) , particularly for the treatment of IFN-α non-responders. IFN-β has been launched for multiple sclerosis and various cancers. A major advantage of using IFN-β is its lack of immunogenicity (Pellicano et al., 2002) . In particular, it has been described as having much fewer adverse side effects than IFN-α (Festi et al., 2004) . So far, it has been launched in Japan and South Korea for the treatment of hepatitis C (Pellicano et al., 2002) . The most obvious disadvantage is the short half-life of IFN-β requiring the IFN to be injected twice daily (Kakizaki et al., 1999) . When using such a high-dosing regimen, the efficacy is in the same range as standard, non-pegylated IFN-α treatment ( Table  2 ). Due to its superior profile over IFN-α in terms of adverse side effects (Festi et al., 2004) , a number of Japanese studies argue in favour of an IFN-β-based therapy (Ikeda et al., 2000; Shiratori et al., 2000; Nomura et al., 2004; Furusyo et al., 1999; Kakizaki et al., 1999) . Analogous to the generation of pegylated IFN-α, serious Standard IFN-α2a Pegylated IFN-α2a efforts have been made on developing a longer-lasting pegylated IFN-β (Pepinsky et al., 2001) , which might also become an improved candidate for hepatitis C trials in the near future.
Ribavirin
Ribavirin, 1-β-D-ribofuranosyl-1H-1,2,4-triazole-3-carboxamide ( Figure 4) in combination with PEG-IFN constitutes the current standard in therapy. The precise mechanism by which ribavirin in combination with IFN exerts its effect against HCV is unknown, since monotherapy with ribavirin had no effect on the elimination of HCV RNA or improving hepatic histology after 6-12 months of therapy and 6 months of follow-up (Di Bisceglie et al., 1992) . Efficacy has been established only in combination with various IFNs (Table 2) . Ribavirin is a pleiotropic antiviral agent that has multiple biological effects. Currently, activities are divided into cellular and direct antiviral effects of ribavirin (Tam et al., 2002) . Direct antiviral actions of ribavirin are: (1) inhibition of the HCV RNA polymerase in its triphosphate form;
(2) inhibition of the viral mRNA (guanine-N 7 -)-methyltransferase of vaccinia virus through the phosphorylated metabolite of ribavirin, RTP (Patterson & Fernandez-Larsson, 1990) , which seems to be of no importance for HCV; and (3) acting as a RNA virus mutagen. Ribavirin exerts its cellular effects through (1) shifting the Th1/Th2 balance towards the Th1 response leading to an increased secretion of antiviral cytokines and supporting the action of IFN-α;
(2) inhibition of inosine 5′-monophosphate dehydrogenase (IMPDH), which represents the rate-limiting step for intracellular GTP de novo synthesis -GTP is a critical building block for viral RNA synthesis; and (3) immunosuppression, which leads to a reduction of inflammatory episodes in the liver. It is likely that the ribavirin activities are compartmentalized. In the peripheral blood, ribavirin Rumi et al., 1996; $ Fattovich et al., 2003; ♠ Senturk et al., 2003; u de Ledinghen et al., 2002; r Furusyo et al., 1999; £ Craxi et al., 2003. modulates the cell-mediated immune response and recruits viral-specific CD4 and CD8 T cells to the liver to fight infection; whilst in the liver, ribavirin is responsible for reducing the cytolytic effect that ordinarily leads to increased liver damage (Tam et al., 2002) .
Being a pleiotropic agent, ribavirin has a number of side effects. It has been shown to be genotoxic and teratogenic in animals. Therefore, the use of contraception is required and pregnancy is contraindicated. In addition, ribavirin might induce haemolytic anaemia, hyperuricaemia and allergy (Durantel et al., 2003) .
Although the precise mechanism of action of ribavirin is still unknown, the majority of the pleiotropic and therapeutically relevant effects of ribavirin rely on the modulation of host cell targets, as is also the case for IFN. The IFN/ribavirin combination treatment shows strong virological and histological responses and an immunosuppressive environment can reduce these responses. Apparently, the most important element of the curative combination treat-ment (IFN-α/ribavirin) is the triggering of a strong antiviral immune response. The effect of ribavirin in enhancing the Th1 response is likely to be its most important molecular mechanism, turning the combination therapy into a more successful strategy than IFN-α monotherapy (Tam et al., 2002) . As such, the existing combination therapy is a host cell modulation approach and, therefore, it is not a novel strategy, but rather proven practice, to modulate the host cell targets in order to fight hepatitis C infections.
Pipeline products
Despite the successes of the IFN and ribavirin combination treatment, it does not lead to the eradication of HCV (Pham et al., 2004) and there are a significant number of non-responders to this therapy (Figure 1) . Researchers in the HCV field are actively searching for the 'third active principle', (in addition to IFN-α and ribavirin) in order eradicate the virus from patients. This search has turned the drug discovery process in hepatitis C into a highly competitive field, filling the current HCV pipeline with 35 drug candidates in various phases of clinical development (Table  1) . Interestingly, 17 candidates rely on an indirect and 16 on a direct antiviral principle, underscoring that clinical practice does not favour one approach over the other although opinion exists that direct antiviral agents might be safer and better, since they directly target essential functions of the virus only. We are convinced that direct antiviral compounds make an important addition to the existing therapies. Nevertheless, direct antiviral agents bear the risk of leading to the development of treatment-resistant viruses (Potter et al. 2004; Schang, 2002) as has been experienced in the field of HIV/AIDS, where the development of resistant viruses against a single novel drug took less than a year after the approval of the particular antiviral agent. Drugs acting on host cell targets are far less likely to be susceptible to resistance formation, in particular those which act on intracellular targets, for example, protein kinases (Schang, 2002) . Even in terms of safety, tolerability and adverse side effects, direct antiviral compounds are by no means superior to standard drugs (De Clercq, 2002; Lee et al., 2003) . In the following sections we summarize the indirect antiviral products that are currently in the HCV pipeline.
Inosine monophosphate dehydrogenase (IMPDH) inhibitors
IMPDH is the key enzyme in the de novo biosynthesis of purine mononucleotides. Inhibitors of IMPDH, such as ribavirin, might affect both RNA and DNA synthesis by reducing the intracellular pools of GTP and dGTP, respectively. Although IMPDH is a cellular target, inhibitors targeted at this enzyme are predicted to inhibit Ribavirin, in addition to its other effects, is also a competitive inhibitor of IMPDH (De Clercq, 2002) . There is significant effort going into the development of second generation compounds such as IMPDH inhibitors with a reduced spectrum of side effects when compared with ribavirin. Viramidine (a second-generation, ribavirin-like inhibitor), merimepodib (VX-497; a less pleiotropic agent inhibiting IMPDH) and mycophenylate mofetil (a noncompetitive inhibitor of IMPDH) (Figure 4 ) do not show any signs of efficacy as monotherapies (Wright et al., 1999; Hügle & Cerny, 2003) . Nevertheless, the IMPDH inhibitors inhibit RNA replication in the replicon system. Interestingly, only partial reversibility of ribavirin's activity was observed through the addition of 200 µM guanosine, whereas it completely abolished the activity of VX-497 and mycophenolic acid (Tam et al., 2002) . This demonstrates that ribavirin possesses additional antiviral components against HCV RNA replication, making it more pleiotropic and maybe leading to higher efficacies in patients when compared with the more specific IMPDH inhibitors.
Novel indirect antiviral agents
Since novel direct antiviral agents are only just entering Phase II trials (Table 1) it is still too early to comment on their clinical antiviral activity. Our impression is that hope is resting on the new IFNs (Table 1) , although these products will be associated with similar disadvantages as the first generation IFNs. They might help to further reduce the total number of IFN-α non-responders, but the IFNs will not be sufficient to completely eradicate HCV. In addition, most new IFNs require subcutaneous, intravenous or intramuscular routes of administration. Consequently, the development of orally available indirect antiviral compounds is highly desirable and should lead to improved treatment compliance. In light of resistance formation and the quasispecies nature of HCV, the Phase II performance of three indirect antiviral compounds, ANA245 [a toll-like receptor (TLR)7 agonist], CPG 10101 (a TLR9 agonist) and IDN-6556 (a caspase inhibitor) are of particular interest (Table 1) . ANA-245 and the pro-drug ANA-971 are immunomodulatory nucleoside analogues acting on TLR7. They are similar in mode of action to the TLR7/8 agonists, the antiviral imidazoquinolinamines, imiquimod (R-837) and resiquimod (R-848) (Hemmi et al., 2002) . TLRs are a family of membrane surface receptors, which are important for pathogen recognition and the induction of the innate immune response. After ligand binding to the exposed surface, the cytoplasmic tail of a prototypical TLR activates a sophisticated signal transduction cascade typically resulting in the secretion of inflammatory cytokines and/or the induction of the IFN pathway (Boehme & Compton, 2004) . TLR7 and TLR9 agonists are known as oral IFN-α inducers (Pawlotsky & McHutchison, 2004) . The TLR7 agonist imiquimod has been approved for the treatment of virally induced anogenital warts (Dockrell & Kinghorn, 2001) . Thus, the TLR agonist principle has already demonstrated efficacy in humans. Unlike imiquimod, for which pre-systemic biotransformation has limited its oral bioavailability, resiquimod may be administered by the oral route and trials are under way to assess its use in anti-HCV therapy (Dockrell & Kinghorn, 2001) . Resiquimod has greater potency for inducing cytokine expression than imiquimod, but whether this will increase its antiviral spectrum is presently unknown. Apparently, intermediate data from the resiquimod HCV trial indicate a lack of specific detectable antiviral activity (Pawlotsky & McHutchison, 2004) . In addition, although resiquimod initially showed efficacy against herpes simplex virus type 2, more recently, Phase III trials were suspended due to lack of efficiency in reducing the recurrence of genital herpes. Nevertheless, resiquimod still shows promise for other viral infections and as a vaccine adjuvant (Wu et al., 2004) .
The greatest challenge in the use of such agents is certainly the delivery of effective doses to the liver. Agents known to induce IFN-α and other cytokines also include high molecular weight compounds such as double-stranded RNA [poly(I:C)] and CpG oligonucleotide derivatives (Vollmer et al. 2004; Pawlotsky & McHutchison, 2004) . Low molecular weight molecules such as resiquimod and the nucleoside analogues ANA-245 and ANA-971 may be more suitable options due to a reasonable probability of oral absorption. Preliminary reports on the Phase II trials for resiquimod indicate a lack of specific detectable antiviral activity, but ANA-245 showed immunologically mediated antiviral activity in a range of viral infection models. However, its oral bioavailability is still limited at high doses and studies in humans are under way to characterize the safety and pharmacology of ANA-245 after intravenous administration (Pawlotsky & McHutchison, 2004) .
IDN-6556 is a novel anti-apoptotic, pan-caspase inhibitor. Its current indications are diseases of the liver with excessive apoptosis such as alcoholic hepatitis and recipients of liver transplantations (Hoglen et al., 2003) . However, being a pan-capase inhibitor, the compound's activity is restricted to liver diseases, since it undergoes first pass effect and shows increased exposure to the liver but not to other organs. Therefore, oral administration resulted in adequate drug concentrations in the liver. In contrast, systemic exposure of IDN-6556 after oral administration was low, which may bear advantages in terms of toxicology of the drug (Hoglen et al., 2003) . In a Phase I clinical study, IDN-6556 was generally well tolerated in patients with mild elevations of their liver transaminases (Valentino et al., 2003) . IDN-6556 is currently in Phase II clinical trials. We want to emphasize that IDN-6556, although acting on host cell targets, is not a true indirect antiviral drug, but rather a hepatoprotective compound directed at improving the symptoms of chronic HCV infection, liver fibrosis and cirrhosis. IDN-6556 has no potential to cure patients with the virus.
Immunomodulators other than IFN-α
The immunomodulatory activities of IFNs have been described above. There are at least two other important immunomodulatory compounds that have demonstrated activity in clinical trials, thymosin α1 (Tα1, Zadaxin) and histamine (Ceplene). Zadaxin has already been launched in a few countries for the treatment of HCV and hepatitis B patients (Billich, 2002) . The 28 amino acid peptide thymosin α1 promotes T-cell maturation and natural killer cell activity (Hügle & Cerny, 2003) . Thymosin α1 was not effective as monotherapy in chronic HCV infection. The virological response rates obtained with the Tα1 plus IFNα combination are similar to those obtained with the combination of IFN-α and ribavirin. Interestingly, Tα1 is well tolerated and, unlike ribavirin, does not add toxicity to the side-effect profile of IFN-α (Billich, 2002) . Currently, there is an ongoing Phase III clinical study of Tα1 with PEG-IFN-α ± ribavirin.
After binding to the H2 receptor, histamine (Ceplene) can activate natural killer cells, similar to Tα1; additionally, it activates T lymphocytes. Phase II studies of histamine in combination with IFN-α ± ribavirin yielded positive results (Hügle & Cerny, 2003) .
Iminosugar derivatives
Iminosugar derivatives have been shown to have activity in surrogate models for HCV infection, for example, the BVDV replication model. Iminosugars such as N-nonyldeoxynojirimycin are known to be competitive inhibitors of the endoplasmic reticulum α-glucosidases I and II . Recently, it has been suggested that some of these iminosugars also antagonize an ion channel activity associated with the p7 HCV protein (Pavlovic et al., 2003) . Even more recently, it was suggested that the activity of these compounds might be a consequence of activating natural killer cells (Mehta et al., 2004) , thus being inducers of the immune response. UT-231-B is such an iminosugar, which is currently being investigated in a Phase II clinical trial (Pawlotsky & McHutchison, 2004) .
In summary, the importance of host cell components essential for viral replication is becoming increasingly clear. Today these targets represent the basis for ~50% of the clinical development efforts in HCV (Tables 1 and 2) . In addition to the clinical trials, there are also great efforts under way in basic and preclinical research with the aim of identifying new host cell targets and inhibitors of these targets (Früh et al., 2002; Katze et al., 2002; Tang et al., 2002; DeFilippis et al., 2003; Klebl, 2004) .
Future treatments and novel targets

Viral targets
There has been a great effort in research and development to generate direct antiviral compounds. Eleven compounds (NS5B polymerase inhibitors: JTK-003, JTK-109, R1479, R803, HCV-086 and NM283; NS3 serine protease inhibitors: VX-950, SCH-6 and BILN2061; the antisense IRES inhibitor ISIS 14803 and the antiviral compound KPE02003002) have entered clinical trials and many more are still under preclinical development. Amongst the 10 proteins encoded by HCV, the most prominent targets are the NS2/3 metalloproteinase, the NS3 serine protease, the helicase part of NS3 and the NS5B RNA-dependent RNA polymerase. There are also efforts ongoing to identify inhibitors for translation of HCV proteins and virion entry (Durantel et al., 2003) .
Novel host cell targets
For a reasoned strategy to develop new medications, a better understanding of the biology of the virus and its interaction with the host may allow the identification of novel and more effective cellular targets. In the more recent history of HCV research, a particular emphasis has been put on the investigation of the virus-host cell interaction and on the role of the virus in interfering with the IFN signal transduction pathways (Heim et al., 1999; . In particular, specific genes and proteins have been found to be consistently up-or down-regulated after infection with HCV (Bigger et al., 2001; Su et al., 2002; Katze et al., 2002) . Intensifying this research might result in targeting host-cell genes as a way of influencing the outcome of a viral infection, just as interferons do in combination with ribavirin. Such an approach might lead to the development of an extremely powerful anti-HCV drug, which may display a broadband antiviral activity, the socalled 'virus silver bullets' . In the following sections, we will describe an HCV-specific approach in which the gastrointestinal glutathione peroxidase (GI-GPx) has been identified as a potential target for the development of an anti-HCV strategy. Then we will concentrate on protein kinases, representing an indirect antiviral, host cell target approach for infectious diseases.
Genomic approaches identifying GI-GPx as a host cell target
Microarray technologies allow the analyses of hundreds of genes in a single experiment. This knowledge has dramatically increased our understanding of the gene regulatory events during the course of viral infection. Utilizing this technology, the alterations of cellular gene expression of experimentally infected chimpanzees were monitored (Bigger et al., 2001 ). As expected, many genes, including those coding for transcription factors, DNA binding proteins, growth factors and cytokines, were deregulated in the livers analysed. The most exciting changes affected several interferon response genes, implying a crucial role of the innate immune response in viral clearance (Bigger et al., 2001) .
In similar studies, Chisari's lab found that all chimps infected with HCV showed gene expression patterns consistent with an IFN-α response Su et al., 2002) . However, transient and sustained viral clearance was correlated with the induction of genes related to IFN-γ response, antigen processing and presentation, and T cell recruitment. The authors speculate that only high viral titres result in the induction of immunological genes that lead to a successful adaptive immune response, while virus-induced genes that reflect the induction of IFN-α do not inhibit viral replication (Su et al., 2002) .
These results may open new avenues for HCV treatment.
Microarray technology was also utilized to examine the interaction between host cell and HCV subgenomic replicon activity at the genomic level (Klebl, 2004; Morbitzer & Herget, 2005) . Differential hybridization of more than 400 cDNAs with probes derived from RNA of one mock-and three replicon-transfected Huh7 cell lines resulted in the identification of several deregulated genes. The level of the GI-GPx mRNA was found to be downregulated in the replicon cell lines up to 20-fold compared with the mock-transfected cell line. Glutathione peroxidases function primarily to counteract oxidative attack, however, they also play roles in signalling (reviewed in Brigelius-Flohé, 1999; Brigelius-Flohé & Flohé, 2003) . Due to their lower expression of GI-GPx, HCV replicon cells were more susceptible to agents producing radical oxygen species (ROS), such as paraquat. Ectopical expression of GI-GPx in replicon cells resulted in a decrease of replicon RNA. On the other hand, up-regulation of GI-GPx expression by gene transfer or addition of retinoic acid caused drastic down-regulation of HCV in the replicon system. Retinoids, which exert their action by signalling through nuclear receptor heterodimers that can activate or silence specific gene networks, may therefore be useful for treating HCV patients (Klebl, 2004) .
Protein kinase targets and protein kinase inhibitors
Protein kinase inhibitors have gained great attention in drug development (Cohen, 1999; Cohen, 2000) , since they are considered amenable to rationale drug design. They are druggable, and have enough of a structural and enzymatic conservation to be applied to an interfamily-like, privi-leged structure approach (Engh & Bossemeyer, 2001; Müller, 2003) .
Currently, drug development in HIV has made progress in targeting host cell kinases. Small molecule kinase inhibitors are typically orally available. No signs of resistance formation have been observed when using these kinase inhibitors in various viral replication assays (Schang, 2004) . Today, there is great interest in the development of kinase inhibitors for most therapeutic indications (Hopkins & Groom, 2002) . Kinase inhibitor development in infectious disease is still in its infancy, but there are a number of reports clearly pointing to essential roles of host cell kinases in viral replication (for a review, see Schang, 2004) .
Presumably, the dsRNA-activated serine/threonine protein kinase PKR is an obvious protein kinase target for the development of an antiviral compound. Like IFN, viral-specific RNAs can activate PKR, which inhibits virus replication and the production of virion progeny. Indeed, nearly all viruses have developed strategies to down-regulate the activity of PKR so that virus replication is not compromised Goodbourn et al., 2000) . NS5A protein interferes with the induction of cellular antiviral signalling by preventing the activation of PKR through double-stranded viral RNA (Pflugheber et al., 2002) . As a consequence, PKR downstream signalling involving IRF1dependent induction of antiviral effector genes and the inhibition of mRNA translation through eIF2α phosphorylation are suppressed (He et al., 2001; Pflugheber et al., 2002) . As a therapeutic, an activator of PKR would be needed in order to inhibit viral replication. The development of pharmacologically active protein kinase activators has been notoriously difficult, so PKR might be eliminated as a viable host cell target. On the other hand, there are many more kinases which play an active role in the replication cycle of HCV (see, for examples, Table 1 in Schang, 2004; MacDonald et al., 2004; Kim et al., 2004) , representing a rich source of better and more amenable potential drug targets. The application of small molecule kinase inhibitors that are involved in viral replication might lead to the inhibition of replication. The protein kinase inhibitor approach carries a lot of hope, since small molecule kinase inhibitors will most probably be orally available, their administration will not lead to resistance formation and they will be affordable.
Interplay between NS5A and cellular protein kinase signalling
The non-structural NS5A protein of HCV has attracted a lot of interest, which is mostly due to its various interactions with the host cell signalling machinery. In cultured cells, NS5A is heavily phosphorylated on serine residues by host cell kinases. Major phosphoacceptor regions have been mapped to serine clusters located in the central region and the C-terminal part of the NS5A molecule (Tanji et al., 1995) . Cellular phosphorylation of the central region around amino acid 2200 requires the presence of additional viral factors and results into the appearance of a basal phosphorylated 56 kDa and a hyperphosphorylated 58 kDa NS5A species on SDS-polyacrylamide gels. Shimotohno and colleagues reported that NS4A co-expression was sufficient to induce the slower migrating NS5A phosphoisoform, whereas results from the Bartenschlager group indicated that a continuous NS3-5A sequence is required for NS5A hyperphosphorylation (Tanji et al., 1995; . These discrepancies might be due to the different NS5A variants and cellular expression systems used. Moreover, mutational analysis identified the highly conserved serine residues at positions 2197, 2201 and 2204 of NS5A as critical for NS5A hyperphosphorylation (Tanji et al., 1997) . In addition, Ser-2194, which is not involved in NS5A hyperphosphorylation, has been mapped as phosphoacceptor site by mass spectrometry (Katze et al., 2000) . NS5A hyperphosphorylation is not only dispensible for HCV RNA replication in cell culture, but the elimination of hyperphosphorylation sites even resulted in significantly enhanced HCV replicon levels, as found for the adaptive Ser-2197 to proline mutation (Blight et al., 2000; Krieger et al., 2001) . In stark contrast, this particular mutant was found to be highly attenuated in comparison with the corresponding wild-type HCV genome when analysed for in vivo infectivity in chimpanzees . This observation indicates an important biological role of NS5A hyperphosphorylation that is not reproduced in the currently available cell culture model systems. Therefore, the as yet unidentified host cell kinase phosphorylating NS5A at Ser-2197 could represent an interesting target for therapeutic intervention.
However, the identification of the relevant enzyme is a challenging task. NS5A hyperphosphorylation only occurs in the presence of other viral components in vivo, which precludes the in vitro testing of purified and/or recombinant protein kinases (Tanji et al., 1995; . In addition to the sites leading to the appearance of the hyperphosphorylated form, NS5A is phosphorylated at Ser-2194 and at residues clustering at the very C-terminal part of the protein by associated cellular protein kinases (Katze et al., 2000; Reed et al., 1997) . Protein kinases A and CK2 were identified as candidate kinases several years ago, based on in vitro results showing NS5A phosphorylation by recombinant enzymes (Ide et al., 1997; Kim et al., 1999) . Very recently, Katze and co-workers identified several NS5A kinases from the Saccharomyces cerevisiae kinome and could further demonstrate in vitro NS5A phosphorylation by related mammalian protein kinases such as CK1δ, AKT1, p70S6K, MEK1 and MKK6 (Coito et al., 2004) . Importantly, these investigators provided evidence for a role of p70S6K as a NS5A kinase in intact cells and went on to suggest Ser-2194 as a potential phosphorylation site, based on the similarity of the surrounding sequence with the consensus phosphorylation motif of p70S6K. It remains to be shown which of the other candidates will prove to be physiological NS5A kinases and might be functionally relevant for the HCV life cycle.
In addition to NS5A regulation by direct phosphorylation, it is also conceivable that protein kinases exert an indirect influence on NS5A function by phosphorylating cellular interaction partners of the HCV protein. The search for NS5A-associated phosphoproteins led to the identification of amphiphysin II, which co-precipitated and co-localized with NS5A in HuH-7 cells expressing HCV components from a self-replicating subgenomic HCV RNA (Zech et al., 2003) . The biological impact of amphiphysin II phosphorylation and NS5A interaction remains to be determined, but this NS5A-associated host cell factor might confer physiologically relevant changes to the membrane environment at the sites of viral replication.
NS5A is not only phosphorylated by cellular kinases and thereby potentially regulated by host cell kinase signalling, but also interferes with and triggers a variety of cellular signalling cascades potentially linked to viral persistence and pathogenesis. The NS5A protein was shown to increase cytoplasmic Ca 2+ levels, which then led to increased production of reactive oxygen species in mitochondria (Gong et al., 2001) . The resulting oxidative stress was found to trigger STAT3 activation, which was possibly via JAK1-mediated tyrosine phosphorylation and might result in STAT3-mediated transcriptional events relevant for HCV-related pathogenesis (Gong et al., 2001; Sarcar et al., 2004) . In addition, NS5A-induced oxidative stress promotes NF-κB activation through tyrosine phosphorylation and subsequent proteolytic degradation of IκBα. Remarkably, the tyrosine kinase ZAP-70 was implicated in this process (Waris et al., 2003) . NF-κB-mediated gene induction and protein expression is likely to counteract apoptotic processes elicited in HCV-infected cells. Furthermore, NS5A protein stimulates a second pro-survival signalling cascade through a direct interaction with the p85 subunit of the phosphatidylinositol 3-kinase (PI3K), which activates PI3K and its downstream target, the Ser/Thr kinase AKT Street et al., 2004) . Thus, NS5A-mediated NF-κB and AKT activation might be part of a virus-induced, antiapoptotic programme, which is essential for viral persistence and eventually contributes to malignant transformation, as manifested in HCC. From this perspective, protein kinases involved in these processes are potential targets for therapeutic intervention.
NS5A protein also interferes with the induction of cellular antiviral signalling by preventing the activation of PKR through double-stranded viral RNA (Pflugheber et al., 2002) . As a consequence, PKR downstream signalling involving IRF1-dependent induction of antiviral effector genes and the inhibition of mRNA translation through eIF2α phosphorylation are suppressed (He et al., 2001; Pflugheber et al., 2002) .
Conflicting data have been published about the effect of NS5A on cyclin-dependent kinase (CDK)-dependent cell cycle progression. While one study claimed that NS5A retards cell growth through an inhibitory interaction with CDK1, other data implicate that NS5A suppresses the expression of the CDK inhibitor p21 WAF1 in a p53dependent manner and thereby stimulates cell proliferation (Arima et al., 2001; Ghosh et al., 1999; Majumder et al., 2001) . Moreover, NS5A was found to modulate mitogenactivated protein kinase (MAPK) signalling in mammalian cells. The interaction of NS5A with tumour necrosis factor (TNF) receptor-associated factor 2 (TRAF2) was shown to enhance TNF-α-induced JNK MAPK activation (Park et al., 2003) . In contrast, binding of NS5A to the adaptor protein Grb2 interfered with the Ras-mediated activation of the ERK MAPK cascade and AP1-dependent gene transcription (Tan et al., 1999; Macdonald et al., 2003) . It is noteworthy that the HCV core protein has an opposing effect on cellular ERK activation. HCV core protein is phosphorylated in intact cells by protein kinase A and protein kinase C, and interacts with 14-3-3 protein in a phosphoserine-dependent manner (Aoki et al., 2000; Lu et al., 2002) . In a complex with 14-3-3 protein, HCV core protein stimulates cellular Raf-1 kinase activity and thereby activates the downstream ERK MAPK pathway. It remains to be established how these antagonizing effects on ERK MAPK signalling are integrated in the presence of all viral components during natural HCV infection.
In summary, NS5A appears to interact extensively with cellular kinase signalling networks ( Figure 5 ). This further implies that various host cell kinases could emerge as viable drug targets from these basic research efforts, which might stimulate drug development activities and ultimately lead to new treatment options for chronic HCV infections.
Regulation of NS5B by phosphorylation
A phosphorylated form of the HCV NS5B RNAdependent RNA polymerase has been observed when expressed in insect cells using a recombinant baculovirus (Hwang et al., 1997) . Very recently, the cellular kinase PRK2 has been identified as being responsible for the phosphorylation of NS5B (Kim et al., 2004) . Knocking down of endogenous PRK2 using PRK2-specific small interfering (si)RNA inhibited RNA replication. Therefore, BM Klebl et al. 84 ©2005 International Medical Press HCV RNA replication is regulated by NS5B phosphorylation by PRK2 (Kim et al., 2004) . Essentially, PRK2 seems to be a good host cell target for inhibiting HCV RNA replication. So far, direct evidence for a role of PRK2 kinase activity in HCV RNA replication is missing. The results with PRK2-specific siRNA, which are inhibitory to RNA replication, look promising but a direct effect of the kinase activity on RNA replication remains to be shown through using either kinase inactive PRK2 mutants or PRK2specific inhibitors, such as HA1077, in the replicon system. As outlined above for the NS5A and NS5B HCV proteins, there is increasing evidence that host cell enzymes, such as protein kinases, are critically involved in HCV replication and pathogenesis. These data provide rationales for highthroughput screening efforts, in which kinase-directed compound libraries consisting of a selection of low molecular weight compounds are tested for antiviral effects in cellular HCV models. Cellular compound screening might provide biologically active compounds, which can then be adapted for recently reported proteomics methods that allow the efficient isolation and identification of cellular drug targets (Godl et al., 2003) . Thus, this forward chemical genetics approach holds great promise for the future and might help identify and characterize host cell kinases that are valid drug targets for antiviral intervention against HCV, but are not essential for host cell physiology and can therefore be blocked with minimal side effects.
Future perspective and conclusions
In the near future, therapies for patients with hepatitis C will continue to rely on IFN-based regimens. The utility of novel IFN preparations, delivery methods and new ribavirin-like drugs needs to be clinically approved, but they are likely to only substitute current therapies. In the HCV arena, clinicians are urgently looking for the so-called 'third active antiviral' principle to be added in order to supplement the existing PEG-IFN-α/ribavirin combination therapy. Novel active principles of therapy will originate from either direct or indirect antiviral approaches.
Many exciting direct antiviral strategies are in early clinical development at present. These direct antiviral agents will need to show synergies with the current therapy or they need to be superior over the existing combination treatment. They must be safe and enhance the SVR. It will take several years to determine their safety, short-and longterm efficacy. As in the HIV-1 treatment setting, multiple drug regimens attacking several viral targets will almost certainly be required to prevent or diminish viral resistance. The newer antiviral and molecular-based approaches have a high level of complexity and they will not be available for routine clinical use in the next couple of years. Nevertheless, we anticipate that direct antiviral drugs, such as NS5B inhibitors, will reach market approval and will be added to the PEG-IFN-α/ribavirin combination therapy.
The efficacies of currently available anti-HCV drugs rely on the modulation of the host cell, either through directly interfering with a host cell target, such as IMPDH, or modulating the immune response, as is the case for IFN. Host cell target-based approaches are not novel per se, instead, they exist as a proven principle when scrutinizing the action of IFN and ribavirin. The beneficial properties of inhibiting host cell targets like IMPDH and ribonucleotide reductase has been mentioned earlier in the field of HIV research. Inhibition of IMPDH and ribonucleotide reductase leads to the depletion of GTP, dGTP and dNTP, respectively, which in turn blocks the activity of the enzyme required for the formation of the DNA provirus, the reverse transcriptase (Ichimura & Levy, 1995; Lori et al., 1994) . Mycophenolic acid and hydroxyurea are inhibitors of the IMPDH and ribonucleotide reductase, respectively. Both compounds have demonstrated antiviral activity by inhibiting HIV replication in infected macrophages (Ichimura & Levy, 1995; Lori et al., 1994) . Adding to the importance of host cell targets and the host cell defense, Levy and colleagues published a series of articles and reviews on the importance of innate immunity and the existence of the CD8+ cell anti-HIV factor (CAF), which mediates the so-called CD8+ cell antiviral non-cytotoxic response (CNAR) (see for example, Levy et al., 2003; Levy, 2003) . CAF appears to be a novel and not yet further characterized antiviral lymphokine with potent clinically relevant anti-HIV properties , further underscoring the importance of innate immunity in controlling viral infections.
We are confident that these and similar host cell approaches are likely to result in the generation of 'virus silver bullets'. These 'virus silver bullets' will not necessarily be associated with a higher level of toxic side effects when compared with today's existing direct antiviral drugs, such as the current anti-HIV, anti-CMV and anti-HSV drugs. Adverse events are well described for HIV patients who are receiving, for example, highly active antiretroviral therapy (HAART) once their T-cell counts drop below 200 CD4 cells/µl. HAART is a 'drug cocktail' consisting of a combination of nucleoside reverse transcriptase inhibitors and non-nucleoside reverse transcriptase inhibitors and/or protease inhibitors. The most prominent adverse effect of HAART is the so-called HIV-associated lipodystrophy syndrome, which includes dyslipidaemia, changes in body fat distribution, insulin resistance, glucose intolerance, metabolic bone disease and lactic acidosis (Monier & Wilcox, 2004) . Ganciclovir and foscarnet are the prototypical anti-CMV and antiherpesviral treatments. Ganciclovir is associated with toxicity to the bone marrow, such as severe neutropaenia. Foscarnet has a lower risk of inducing neutropaenia, but is reported to cause renal toxicity (Reusser et al., 2002) . In essence, there are major problems with all of today's existing 37 licensed antiviral drugs (De Clercq, 2004) in terms of in drug-related side effects (De Clercq, 2002; Lee et al., 2003) . Outside the area of antiinfectives, compounds and drugs are always directed against cellular ('host' cell) targets and do not cause more difficulties in terms of adverse effects than when compared with standard antivirals. Given the advantages in resistance formation and the higher likelihood of coming across a druggable target (for example, a protein kinase) we anticipate that the efforts in developing compounds acting on host cell targets will result in the generation of such 'virus silver bullets', thus turning the host cell approach in infectious disease into a proven and successful strategy once more. Novel combination therapies based on the modulation of various host and viral targets will probably become the future approach to treatment of hepatitis C in order to reduce or eliminate drug resistance and to eradicate the virus.
